In short
This guide merges Chinese and international guidance on invasive pulmonary fungal disease, covering aspergillosis, cryptococcosis, and candidiasis diagnosis and antifungal strategies.
What this guide covers: Understanding · Graded · Aspergillosis · Cryptococcosis · Preventing
Understanding
The Disease Invasive pulmonary fungal disease affects mainly immunocompromised patients, with aspergillosis, cryptococcosis, and candidiasis as the leading forms. The lung is the most common target organ, and rates are rising in transplant and cancer care.
Graded
Diagnosis Guidelines use three levels: proven, probable, and possible. Proven needs tissue or sterile-fluid proof. Probable combines host factors, clinical signs, and microbiology. This framework guides, but clinical judgment stays essential.
Aspergillosis
Management For invasive pulmonary aspergillosis, voriconazole is the preferred first treatment. Lipid amphotericin B, isavuconazole, or an echinocandin are alternatives. Therapy usually lasts six to twelve weeks based on response and immune recovery.
Cryptococcosis
And Candidiasis Pulmonary cryptococcosis often needs fluconazole or amphotericin B with flucytosine for severe disease. Candida pneumonia is uncommon; treatment follows susceptibility, using fluconazole or an echinocandin when indicated.
Preventing
Infection High-risk patients may receive preventive antifungals. Reversing immune suppression, such as lowering steroids, and careful monitoring improve outcomes. Avoid unnecessary prolonged antifungal use.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.


